Our overall hedge fund sentiment score for RAPT is 85. (NASDAQ:RAPT) is not the most popular stock in this group but hedge fund interest is still above average. On the other hand Douglas Dynamics Inc (NYSE: PLOW) is the least popular one with only 7 bullish hedge fund positions. PAE Incorporated (NASDAQ: PAE) is the most popular stock in this table.
That figure was $45 million in RAPT's case. View table here if you experience formatting issues.Īs you can see these stocks had an average of 12 hedge funds with bullish positions and the average amount invested in these stocks was $122 million. This group of stocks' market caps are closest to RAPT's market cap. (NASDAQ: TIG), and Keros Therapeutics, Inc.
(NASDAQ: WRLD), PAE Incorporated (NASDAQ: PAE), Douglas Dynamics Inc (NYSE: PLOW), Trean Insurance Group, Inc. (NASDAQ: AKUS), Gogo Inc (NASDAQ: GOGO), World Acceptance Corp. Let's also examine hedge fund activity in other stocks similar to RAPT Therapeutics, Inc. The other funds with new positions in the stock are Ken Greenberg and David Kim's Ghost Tree Capital, Michael Rockefeller and KarláKroeker's Woodline Partners, and Efrem Kamen's Pura Vida Investments. Manfred Yu's Acuta Capital Partners also initiated a $7.7 million position during the quarter. Avoro Capital Advisors (venBio Select Advisor) had $18.5 million invested in the company at the end of the quarter. Avoro Capital Advisors (venBio Select Advisor), managed by Behzad Aghazadeh, initiated the most outsized position in RAPT Therapeutics, Inc. With a general bullishness amongst the heavyweights, specific money managers have jumped into RAPT Therapeutics, Inc. Ghost Tree Capital is also relatively very bullish on the stock, dishing out 1.07 percent of its 13F equity portfolio to RAPT. (NASDAQ:RAPT), around 2.1% of its 13F portfolio. In terms of the portfolio weights assigned to each position Acuta Capital Partners allocated the biggest weight to RAPT Therapeutics, Inc. Millennium Management, Ghost Tree Capital, and Woodline Partners were also very fond of the stock, becoming one of the largest hedge fund holders of the company. Trailing Avoro Capital Advisors (venBio Select Advisor) was Acuta Capital Partners, which amassed a stake valued at $7.7 million. (NASDAQ:RAPT), with a stake worth $18.5 million reported as of the end of September. More specifically, Avoro Capital Advisors (venBio Select Advisor) was the largest shareholder of RAPT Therapeutics, Inc.
0 kommentar(er)
